Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP960629.RAwnO9pyfNAVj02Lb6ncEIK5Jnlo1J-cgBeTddwjL2iGE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP960629.RAwnO9pyfNAVj02Lb6ncEIK5Jnlo1J-cgBeTddwjL2iGE130_assertion type Assertion NP960629.RAwnO9pyfNAVj02Lb6ncEIK5Jnlo1J-cgBeTddwjL2iGE130_head.
- NP960629.RAwnO9pyfNAVj02Lb6ncEIK5Jnlo1J-cgBeTddwjL2iGE130_assertion description "[In the present study, we found: (1) a variation in HSPG and the expressions of integrins alpha(upsilon)beta(3) and alpha(upsilon)beta(5) between OVCAR-3 and SKOV-3ip; (2) that 17beta-estradiol was shown to significantly stimulate cell proliferation and integrin beta(5) expression in certain ovarian cancer cell lines; and (3) integrintargeted A520/N584RGD-rAAV2, which has alternative interactivity with integrins and abrogates the binding capacity HSPG, showed much higher gene transduction efficiency in ovarian cancer cells than rAAV2 in the presence/absence of 17beta-estradiol.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP960629.RAwnO9pyfNAVj02Lb6ncEIK5Jnlo1J-cgBeTddwjL2iGE130_provenance.
- NP960629.RAwnO9pyfNAVj02Lb6ncEIK5Jnlo1J-cgBeTddwjL2iGE130_assertion evidence source_evidence_literature NP960629.RAwnO9pyfNAVj02Lb6ncEIK5Jnlo1J-cgBeTddwjL2iGE130_provenance.
- NP960629.RAwnO9pyfNAVj02Lb6ncEIK5Jnlo1J-cgBeTddwjL2iGE130_assertion SIO_000772 19026163 NP960629.RAwnO9pyfNAVj02Lb6ncEIK5Jnlo1J-cgBeTddwjL2iGE130_provenance.
- NP960629.RAwnO9pyfNAVj02Lb6ncEIK5Jnlo1J-cgBeTddwjL2iGE130_assertion wasDerivedFrom befree-20150227 NP960629.RAwnO9pyfNAVj02Lb6ncEIK5Jnlo1J-cgBeTddwjL2iGE130_provenance.
- NP960629.RAwnO9pyfNAVj02Lb6ncEIK5Jnlo1J-cgBeTddwjL2iGE130_assertion wasGeneratedBy ECO_0000203 NP960629.RAwnO9pyfNAVj02Lb6ncEIK5Jnlo1J-cgBeTddwjL2iGE130_provenance.